Elevance Health, Inc. $ELV Holdings Decreased by IPG Investment Advisors LLC

IPG Investment Advisors LLC trimmed its position in Elevance Health, Inc. (NYSE:ELV) by 65.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 2,212 shares of the company’s stock after selling 4,143 shares during the period. IPG Investment Advisors LLC’s holdings in Elevance Health were worth $775,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in ELV. Sei Investments Co. increased its holdings in shares of Elevance Health by 7.7% in the 2nd quarter. Sei Investments Co. now owns 163,668 shares of the company’s stock valued at $63,666,000 after acquiring an additional 11,745 shares during the last quarter. Glenview Trust co increased its holdings in shares of Elevance Health by 41.5% in the 2nd quarter. Glenview Trust co now owns 1,619 shares of the company’s stock valued at $630,000 after acquiring an additional 475 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of Elevance Health by 6.9% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 65,945 shares of the company’s stock valued at $25,650,000 after acquiring an additional 4,272 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Elevance Health by 5.0% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,371 shares of the company’s stock valued at $16,478,000 after acquiring an additional 2,012 shares during the last quarter. Finally, Quantinno Capital Management LP increased its holdings in shares of Elevance Health by 111.8% in the 2nd quarter. Quantinno Capital Management LP now owns 43,911 shares of the company’s stock valued at $17,080,000 after acquiring an additional 23,180 shares during the last quarter. 89.24% of the stock is currently owned by institutional investors.

Elevance Health Price Performance

Shares of ELV opened at $391.00 on Thursday. The company has a market cap of $84.91 billion, a P/E ratio of 16.63, a PEG ratio of 2.20 and a beta of 0.66. The stock has a fifty day moving average price of $339.83 and a 200 day moving average price of $337.98. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $408.00.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm’s revenue was up 1.5% on a year-over-year basis. During the same period in the prior year, the business earned $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, research analysts forecast that Elevance Health, Inc. will post 26.91 earnings per share for the current year.

Elevance Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio is presently 29.26%.

Wall Street Analyst Weigh In

ELV has been the subject of a number of research analyst reports. Mizuho boosted their price target on Elevance Health from $385.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, May 20th. Leerink Partners set a $364.00 price target on Elevance Health in a report on Thursday, April 23rd. Deutsche Bank Aktiengesellschaft upgraded Elevance Health from a “hold” rating to a “buy” rating and boosted their price target for the company from $363.00 to $498.00 in a report on Wednesday, May 20th. Citigroup upgraded Elevance Health to a “buy” rating in a research note on Wednesday, April 29th. Finally, Sanford C. Bernstein upped their price objective on Elevance Health from $384.00 to $424.00 and gave the stock an “outperform” rating in a research note on Friday, April 24th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $403.11.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.